Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.
Synergy time-kill testing of levofloxacin alone and in combination with CHP-105, a representative DnaK inhibitor, against 50 gram-negative rods demonstrated that 34 of the 50 strains tested showed significant synergy between levofloxacin and CHP-105 after 12 h and 24 h. Fourteen of these 34 organisms were quinolone resistant (levofloxacin MICs of > or =4 microg/ml).
Credito
Kim
K
Department of Pathology, Hershey Medical Center, PA 17033, USA.
Lin
Gengrong
G
Koeth
Laura
L
Sturgess
Michael A
MA
Appelbaum
Peter C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology; D015169:Colony Count, Microbial; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D029968:Escherichia coli Proteins / Q000037:antagonists & inhibitors*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D018840:HSP70 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D019476:Insect Proteins / Q000494:pharmacology; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D004338:Drug Combinations; D029968:Escherichia coli Proteins; D018840:HSP70 Heat-Shock Proteins; D019476:Insect Proteins; C087710:pyrrhocoricin protein, Pyrrhocoris apterus; D064704:Levofloxacin; D015242:Ofloxacin; C063842:dnaK protein, E coli